Veracyte director exercises 30,000 options, sells 43,196 shares

Veracyte, Inc. (VCYT) reported an insider transaction by a director.

Rhea-AI Filing Summary

Veracyte, Inc. (VCYT) reported an insider transaction by a director. On 11/05/2025, the insider exercised stock options for 30,000 shares at exercise prices of $5.28, $7.94, and $7.60, then sold 43,196 shares in multiple trades at weighted average prices ranging from $41.10 to $46.40. These transactions were made pursuant to a Rule 10b5-1 trading plan adopted on December 9, 2024.

Following the transactions, the insider directly beneficially owns 30,468 shares. The options exercised were fully vested, tied to grants expiring on 06/20/2026, 06/07/2027, and 06/07/2028.

Insider Trade Summary

Exercise and sale activity reported; no spread calculated

Exercise and Sale 12 txns

Insider JONES EVAN/ FA

Role Director

Sold 43,196 shs ($1.95M)

Approx. gross sale proceeds $1.95M

Approx. exercise cost $208K

Type	Security	Shares	Price	Value
Exercise	Stock Option (right to buy)	10,000	$0.00	$0.00
Exercise	Stock Option (right to buy)	10,000	$0.00	$0.00
Exercise	Stock Option (right to buy)	10,000	$0.00	$0.00
Exercise	Common Stock	10,000	$5.28	$53K
Exercise	Common Stock	10,000	$7.94	$79K
Exercise	Common Stock	10,000	$7.60	$76K
Sale	Common Stock	408	$41.7431	$17K
Sale	Common Stock	1,126	$43.0329	$48K
Sale	Common Stock	10,837	$43.8038	$475K
Sale	Common Stock	5,872	$45.0682	$265K
Sale	Common Stock	24,296	$45.7273	$1.11M
Sale	Common Stock	657	$46.3756	$30K

Holdings After Transaction: Stock Option (right to buy) — 0 contracts (Direct); Common Stock — 30,468 shares (Direct)

Footnotes (8)

1. F1. The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on December 9, 2024.
2. F2. Represents weighted average sales price. Sale prices for the transactions range from $41.10 to $41.97. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.
3. F3. Represents weighted average sales price. Sale prices for the transactions range from $42.285 to $43.20. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.
4. F4. Represents weighted average sales price. Sale prices for the transactions range from $43.29 to $44.29. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.
5. F5. Represents weighted average sales price. Sale prices for the transactions range from $44.335 to $45.335. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.
6. F6. Represents weighted average sales price. Sale prices for the transactions range from $45.34 to $44.33. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.
7. F7. Represents weighted average sales price. Sale prices for the transactions range from $46.35 to $46.40. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.
8. F8. The option is fully vested.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider activity did VCYT report on 11/05/2025?

A director exercised options for 30,000 shares and sold 43,196 shares in multiple transactions on 11/05/2025.

How many Veracyte options were exercised and at what prices?

Options for 30,000 shares were exercised at $5.28, $7.94, and $7.60.

At what prices were VCYT shares sold?

Weighted average sale prices included $41.7431, $43.0329, $43.8038, $45.0682, $45.7273, and $46.3756, with ranges from $41.10 to $46.40.

How many VCYT shares does the insider own after these trades?

The insider directly beneficially owns 30,468 shares after the reported transactions.

Was the VCYT insider trading under a 10b5-1 plan?

Yes. The trades were made under a Rule 10b5-1 plan adopted on December 9, 2024.

What are the expiration dates of the exercised VCYT option grants?

The related grants carry expirations on 06/20/2026, 06/07/2027, and 06/07/2028.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/07/2025 - 04:10 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

JONES EVAN/ FA

(Last) (First) (Middle)

6000 SHORELINE COURT

SUITE 300

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
VERACYTE, INC. [ VCYT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/05/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/05/2025		M(1)		10,000	A	$5.28	53,664	D
Common Stock	11/05/2025		M(1)		10,000	A	$7.94	63,664	D
Common Stock	11/05/2025		M(1)		10,000	A	$7.6	73,664	D
Common Stock	11/05/2025		S(1)		408	D	$41.7431(2)	73,256	D
Common Stock	11/05/2025		S(1)		1,126	D	$43.0329(3)	72,130	D
Common Stock	11/05/2025		S(1)		10,837	D	$43.8038(4)	61,293	D
Common Stock	11/05/2025		S(1)		5,872	D	$45.0682(5)	55,421	D
Common Stock	11/05/2025		S(1)		24,296	D	$45.7273(6)	31,125	D
Common Stock	11/05/2025		S(1)		657	D	$46.3756(7)	30,468	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$5.28	11/05/2025		M(1)			10,000	(8)	06/20/2026	Common Stock	10,000	$0	0	D
Stock Option (right to buy)	$7.94	11/05/2025		M(1)			10,000	(8)	06/07/2027	Common Stock	10,000	$0	0	D
Stock Option (right to buy)	$7.6	11/05/2025		M(1)			10,000	(8)	06/07/2028	Common Stock	10,000	$0	0	D

Explanation of Responses:

1. The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on December 9, 2024.

2. Represents weighted average sales price. Sale prices for the transactions range from $41.10 to $41.97. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.

3. Represents weighted average sales price. Sale prices for the transactions range from $42.285 to $43.20. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.

4. Represents weighted average sales price. Sale prices for the transactions range from $43.29 to $44.29. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.

5. Represents weighted average sales price. Sale prices for the transactions range from $44.335 to $45.335. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.

6. Represents weighted average sales price. Sale prices for the transactions range from $45.34 to $44.33. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.

7. Represents weighted average sales price. Sale prices for the transactions range from $46.35 to $46.40. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.

8. The option is fully vested.

Remarks:

	/s/ Jonathan Wygant, as attorney-in-fact	11/07/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.